Abstract
BRAF-MEK inhibitor combination targeted therapies offer a personalized treatment approach for melanoma patients with a BRAF+ V600E/K mutation. This study quantified metastatic melanoma patient preferences for treatment attributes that differ among various BRAF-MEK combination targeted therapy options.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
